NEW YORK — CAR T-cell therapy has a known weakness. Against solid tumors, the engineered immune cells burn out. They exhaust. They stop fighting.
Now a team of researchers says it has found the molecular switch responsible for that exhaustion. And they have shown, in mice, that turning it off changes everything.
The switch is a transcription factor called NFIL3. Transcription factors act as master regulators of gene activity. They tell other genes what to do. In this case, NFIL3 drives T-cell exhaustion — the process that makes engineered cancer-killing cells go dormant before they finish the job.
Michel Sadelain and Judith Feucht led the work. They are based at Columbia University and University Hospital Tubingen. The team used CRISPR gene editing to delete the gene that produces NFIL3. The modified CAR T cells stayed active. They multiplied. They kept attacking.
In mouse models of solid tumors, the edited cells delivered stronger tumor control. Survival times extended. That is a big deal because solid tumors — breast, lung, pancreatic — make up the majority of human cancers. Current CAR T therapies work well against some blood cancers. Against solid masses, they fail.
The finding was published in the journal Cancer Discovery. That matters. It means the work has passed peer review. It also means this is still early-stage laboratory research. No patient has received these edited cells. No clinical trial has started.
But the logic of the approach is what has researchers optimistic. They did not target a specific tumor type. They targeted the biology of exhaustion itself. That is why they believe the impact could be broad. If the switch works the same way across different cancers, the fix could too.
The team screened multiple transcription factors before settling on NFIL3. They were looking for the primary driver of exhaustion. They found it. That identification is the core of the discovery. Without it, there is no target. With it, there is a path forward.
CRISPR made the edit possible. The gene-editing tool allowed the researchers to delete the NFIL3 gene with precision. The result was a CAR T cell that did not tire. It kept producing. It kept killing.
There are caveats. Mouse models are not humans. The immune systems are different. The tumors are different. The timeline from lab to clinic is long. Many promising discoveries never become treatments. People with cancer should consult their doctor about appropriate treatment options. This research, while promising, is still in its early stages.
Still, the finding represents a significant step. CAR T therapy transformed blood cancer treatment. But solid tumors remained a wall. This work suggests the wall has a door. The door is NFIL3. The key is CRISPR.
The researchers have not announced plans for human trials. They have not named a timeline. They have published their data. That is where the story stands. A master switch, identified. A way to disable it, shown. The rest is work.
